North Haven Medical Center
Yale-New Haven Hospital
North Haven, CT
Accepting patients
Belantamab Mafodotin and Elotuzumab
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1/2
Accepting patients
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Monoclonal Antibody
- CD38
- Phase 3
Accepting patients
Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
- Monoclonal Antibody
- CD38
- Maintenance
- Randomization
- Phase 3
Accepting patients
Dara-SVD vs. Dara-RVD
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
- SINE
- Quadruplet Therapy
- Phase 2
Accepting patients
TECVAYLI
A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma
- Bispecific Antibody
- CELMoD
- BCMA
- Phase 1